logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Discovery Labs Surges as FDA Agrees to Updated Surfaxin Specifications

By  +Follow October 4, 2013 2:07AM
Share:
Tickers Mentioned:

Shares of Discovery Laboratories, Inc. (DSCO) leapt forward immediately in Friday trading after the U.S. Food and Drug Administration agreed to updated product specifications for Surfaxin® Intratracheal Suspension, the company’s approved drug for the prevention of respiratory distress syndrome, or RDS, in premature infants at high risk for RDS. Surfaxin is the first synthetic, peptide-containing surfactant approved by the FDA and the only alternative to animal-derived surfactants. 

A surfactants is a liquid that coats the inside of the lungs and helps to keep them open.  Premature infants are not able to produce enough surfactant, resulting in lungs collapsing and the infant having difficulty breathing.

Other surfactants on the market are Survanta (beractant), Infasurf (calfactant) and Cornerstone Therapeutics’ (CRTX) Curosurf (poractant alpha), but, as mentioned, these drugs are derived from animals. Curosurf sales in the second quarter were $11.3 million, its best quarter on record. Italy’s Chiesi Farmaceutici, which already owns 58 percent of Cornerstone, agreed in September to pay $115 million for the remaining stake in the company that it didn’t already own to take it private.

In March 2012, the FDA approved Surfaxin for RDS and the drug was expected to be launched in the fourth quarter of 2013, but Discovery determined through a routine review that one of its analytical chemistry methods used to assess the performance of Surfaxin required improvement, delaying the launch by two quarters. 

Then in April, Warrington, Pennsylvania-based Discovery disclosed that the FDA requested more information on product specifications of Surfaxin, further delaying the launch and sending shares of DSCO plunging about 40 percent to lows of $1.50.

Discovery has now met the demands of the FDA that have plagued product launch. The company has initiated manufacturing of Surfaxin for its planned commercial introduction in the fourth quarter of 2013.

"We are pleased that the FDA has agreed with our updated product specifications and are appreciative of the process that has lead to this decision," said John G. Cooper, chief executive of Discovery in a statement today. "Surfaxin represents the first milestone in our goal of transforming the treatment of RDS and is an important medical advancement for the neonatology community and parents of preterm infants who will soon have an effective alternative to animal-derived surfactants for the prevention of RDS."

Shares of DSCO drove north of $3.00 shortly after Friday’s opening from Thursday’s closing price of $1.97, but have cooled off to $2.75 1-1/2 hours into the trading session for gains of around 40 percent.  Through Thursday’s close, shares were down about 6 percent in 2013, but have reversed the losses with today’s climb

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

Results for dsco
Chris Kochiya
2 Sep 14 18:10:07
$DSCO -looks like a nice long entry point to me. A close below the 50-day ma would indicate weakness to me. Otherwise, higher prices likely.
Jet Life PennyStock$
2 Sep 14 00:29:20
Dollar$OnPennies: $DSCO Gallery View http://t.co/S5T1ZS3yWu
Biz Headlines
29 Aug 14 15:15:26
$DSCO: Discovery Laboratories Inc Stock Downgraded (DSCO) http://t.co/jZUQlhbBiQ http://t.co/NMTGoSbiYd
Market News Desk
28 Aug 14 08:15:35
$DSCO: Discovery Laboratories Now Covered by Stifel Nicolaus (DSCO) http://t.co/lWHBTSVzyG http://t.co/oigFCiXbXd
Wall Street News
28 Aug 14 07:15:29
$DSCO: Discovery Laboratories Inc. (DSCO) in Focus: Stock Up 6% http://t.co/0yQr6cAdnK http://t.co/CqjUgw7SBV
K. Trox
28 Aug 14 06:02:17
Did a lot of reading on these drugs in development now. More familiar with everything going on now $OREX $DSCO $ALIM $PSDV $KERX $DVAX $OPXA
K. Trox
27 Aug 14 07:56:52
September is huge for biotech: $AMRN, $CPRX $KERX $ALIM $DSCO $XOMA $LPCB and others all have FDA or data
				
				
By  +Follow October 4, 2013 2:07AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.